Rubius Therapeutics — Investor Presentation (January 2021)
28 slides from Rubius Therapeutics's investor presentation, Jan 11, 2021
Slide 1: Realizing the Power of RED: A New Era in Cellular Medicine
JANUARY 2021 REALIZING THE POWER OF REDsv™ A NEW ERA IN CELLULAR MEDICINE 1
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation may contain forward - looking statements . Forward - looking statements are neither historical facts nor assurances of future performance . Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business
Slide 3: Strong Execution of Key Priorities
Completed dosing of 5 cohorts (n=14) in Phase 1/2 RTX - 240 solid tumor clinical trial; generating clinical data DELIVERING ON CRITICAL MILESTONES AND BUILDING THE RIGHT CULTURE Dosing patients in Phase 1 arm of RTX - 240 clinical trial in relapsed/refractory acute myeloid leukemia (AML) Screening p
Slide 4: Anticipated Upcoming Catalysts and Operational Objectives
Present additional clinical data for RTX - 240 solid tumor trial in early 2021, and submit to a scientific conference Anticipated Upcoming Catalysts and Operational Objectives 4 AN INTEGRATED DEVELOPMENT COMPANY Continue to enroll patients in RTX - 240 AML clinical trial Dose first patient in RTX -
Slide 5: The Promise of the RED PLATFORM
The Promise of the RED PLATFORM ® EXPANSION & DIFFERENTIATION GENETIC ENGINEERING WITH LENTIVIRUS 100 - 1000’s OF DOSES EARLY PROGENITOR CELLS ENUCLEATION & MATURATION RED CELL THERAPEUTIC SINGLE HEALTHY O - DONOR 5 FEATURES • Consistent research and manufacturing process • Only modification is lent
Slide 6: Red Cell Therapeutics: The Future of Cellular Therapy
Red Cell Therapeutics™: The Future of Cellular Therapy 6 Modular platform that mimics immune biology Cellular presentation of potent immune agonists & cytokines POTENTIALLY TRANSFORMATIVE ALLOGENEIC CELLULAR THERAPIES POTENT ADVANTAGEOUS TOLERABILITY SCALABLE Biodistribution confined to vasculature
Slide 7: Fully Owned Manufacturing and Integrated Technical Development & Operations
Fully Owned Manufacturing and Integrated Technical Development & Operations 7 Significant potential to expand manufacturing capabilities based on future needs Providing cGMP clinical supply for RTX - 240 trial and RTX - 321 trials Small - scale production, process development, cGMP manufacturing, an
Slide 8: Robust Manufacturing Capabilities
Scaled platform from 1L to 10L bioreactors Scaled platform to 50L bioreactors 28 - day liquid in - vial shelf life for RTX - 240 52 - day liquid in - vial shelf life for RTX - 240 Produced consistent drug supply for RTX - 240 trials in 50L bioreactors Increased productivity in 50L bioreactor for RTX
Slide 9: RED PLATFORM Enables Multiple Modalities
BROAD IMMUNE SYSTEM STIMULATION Stimulate adaptive and innate immunity • Potential broad therapeutic window of agonists expressed on cell surface • Biodistribution may reduce toxicities of agonists Realize the power of immune agonists CANCER AUTOIMMUNE DISEASES ANTIGEN - SPECIFIC IMMUNE STIMULATION
Slide 10: Clinical-Stage Company Building a Broad Wholly Owned Pipeline
Clinical - Stage Company Building a Broad Wholly Owned Pipeline PRODUCT CATEGORY PROGRAM PRECLINICAL IND ENABLING PHASE 1 CANCER RTX - 240 RTX - 240 RTX - 321 aAPC (HPV 16+) RTX - 224 RTX - aAPC AUTOIMMUNE DISEASES RTX - T1D R/R Solid Tumors Type 1 Diabetes R/R Solid Tumors R/R Acute Myeloid Leukemi
Slide 11: Broad Immune System Stimulation
RTX - 240: BROAD IMMUNE SYSTEM STIMULATION 11
Slide 12: Enrolling Phase 1/2 Clinical Trial in Advanced Solid Tumors & Phase 1 Arm in AML
RTX - 240: Enrolling Phase 1/2 Clinical Trial in Advanced Solid Tumors & Phase 1 Arm in Relapsed/Refractory AML 12 BROAD IMMUNE SYSTEM STIMULATION POTENTIAL BENEFITS: • Activate existing agonist pathways leading to enhanced potency • Improve anti - tumor activity • Overcome resistance to immunothera
Slide 13: Proposed Mechanism of Action
Proposed Mechanism of RTX - 240 PERIPHERAL BLOOD SPLEEN NK cell RTX RBC T cell RTX RBC T cell Red pulp White pulp NK cell T cell NK cell Tumor cell Potential for enhanced efficacy and safety by confining RTX - 240 to the vasculature 13 4 Activation Trafficking Tumor killing Expansion 1 2 3 1 2 3 4
Slide 14: Tumor-Specific T Cells Exist in the Spleen and Peripheral Blood
Exhausted anti - tumor T cell Active anti - tumor T cell Spleen Blood vessel Tumor Spleen Blood vessel Tumor Wu, TD, et al. Grogan JL. Peripheral T Cell Expansion Predicts Tumour Infiltration and Clinical Response. Nature 2020 Beltra JC, et al. Wherry J. Developmental Relationships of Four Exhausted
Slide 15: Preclinical Data Demonstrated Mechanism of Action In Vivo
T AND NK CELL EXPANSION IN BLOOD (In Vivo with healthy mice) 0 2×10 5 4×10 5 0 5×10 5 1×10 6 1.5×10 6 2×10 6 Number of CD8 RTX - 240 Preclinical Data Demonstrated Mechanism of Action In Vivo 15 CD8+ T Cells NK Cells 0 20 40 60 80 0 5 10 15 20 %CD8 of CD45+ %NK of CD45+ Model details: Normal mice; 4
Slide 16: mRBC-240 Resulted in No Liver Toxicity and Inhibited Tumor Growth as Monotherapy
mRBC - 240 Resulted in No Liver Toxicity and Significantly Inhibited Tumor Growth as Monotherapy Compared to Anti - 4 - 1BB mAb In Vivo m R C T - C T R L m R C T - 2 1 2 1 E 9 P D 1 m A b 1 5 0 u g m R C T - 2 1 2 1 E 9 + P D 1 m A b 1 5 0 u g 4 - 1 B B m A b 2 0 0 u g 4 - 1 B B m A b 5 0 u g 0 50 1
Slide 17: Clinical Development Program & Key Takeaways from Initial Data
17 RTX - 240 CLINICAL DEVELOPMENT PROGRAM & KEY TAKEAWAYS FROM INITIAL DATA
Slide 18: Solid Tumor Clinical Trial Objectives
RTX - 240 Solid Tumor Clinical Trial Objectives 18 • Determine safety and tolerability, define recommended Phase 2 dose (RP2D) and interval of RTX - 240 • Assess pharmacodynamic (PD) activity of RTX - 240 measured by changes in T and NK cell number and function relative to baseline: – Activation of
Slide 19: Solid Tumor Clinical Development Plan
RTX - 240 Solid Tumor Clinical Development Plan RTX - 240 Phase 2: Tumor - Specific Expansion Cohort #2 ENROLLING: Phase 1 Dose Escalation 5 Dose Cohorts Completed to Date (n=14) Phase 2: Tumor - Specific Expansion Cohort #1 19 • R/R or locally advanced, unresectable solid tumor for which no standar
Slide 20: Key Takeaways from Initial Data
In the majority of patients (n=8), all of the following were observed across dose levels: ▪ Activation of NK cells ▪ Activation of T cells ▪ Expansion of NK cells ▪ Expansion of T cells Key Takeaways from Initial Data – RTX - 240 Stimulates Adaptive and Innate Immunity, Supporting Proof of Mechanism
Slide 21: AML Clinical Development Plan
• Determine safety and tolerability, MTD, RP2D and dosing interval of RTX - 240 • Assess PD effects of RTX - 240 as measured by changes in NK and T cell number and function relative to baseline in peripheral blood and paired bone marrow biopsies • Measure anti - tumor activity by ORR • Assess PK of
Slide 22: RTX-321: Antigen-Specific Immune Stimulation
RTX - 321: ANTIGEN - SPECIFIC IMMUNE STIMULATION 22
Slide 23: Rubius' First Engineered aAPC Will Target HPV+ Tumors
ANTIGEN PRESENTATION Rubius’ First Engineered aAPC will Target HPV+ Tumors – IND Cleared and Screening Patients for Phase 1 Clinical Trial SELECTIVE TUMOR KILLING BY EXPANDING TUMOR - SPECIFIC T CELLS BROAD IMMUNE SYSTEM STIMULATION LEADS TO EPITOPE SPREADING • Replicate immune system function to ac
Slide 24: Re-challenge of Cured Mice Demonstrates Memory and Epitope Spreading
0 10 20 30 40 0 2000 4000 6000 OT-1 (5E5) naïve group mRBC-OVA-4-1BBL-IL-12 previously cured (n=7) 7/7 cures 0 10 20 30 0 2000 4000 6000 OT-1 (5E5) naïve group mRBC-OVA-4-1BBL-IL-12 previously cured (n=7) 1E5 EL4 3/7 delayed 3/7 cures Re - challenge with EL4, the “parental” line of EG7.OVA. EL4 expr
Slide 25: RTX-321 Clinical Development Plan in Advanced HPV+ Tumors
RTX - 321 Clinical Development Plan in Advanced HPV+ Tumors SCREENING : Phase 1 Dose Escalation Phase 2 Expansions in Specific Indications 25 PERSISTENT, RECURRENT, OR METASTATIC, UNRESECTABLE, HPV 16 - POSITIVE CANCERS • Cervical cancer, head and neck squamous cell cancer (HNSCC), or squamous cell
Slide 26: Expected Catalysts
biusTherapeutics EXPECTED CATALYSTS
Slide 27: Anticipated Upcoming Catalysts and Operational Objectives
Present additional clinical data for RTX - 240 solid tumor trial in early 2021, and submit to a scientific conference Anticipated Upcoming Catalysts and Operational Objectives 27 AN INTEGRATED DEVELOPMENT COMPANY Continue to enroll patients in RTX - 240 AML clinical trial Dose first patient in RTX -
Slide 28: Realizing the Power of RED: A New Era in Cellular Medicine
REALIZING THE POWER OF RED™ A NEW ERA IN CELLULAR MEDICINE 28
Rubius Therapeutics — Investor Presentation (January 2021) on 6ix